OLN vs OXY: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: OXY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. OLN and OXY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined OLN and OXY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Olin Corporation, incorporated in Virginia in 1892 and headquartered in Clayton, Missouri, is a vertically integrated global manufacturer and distributor of chemical products and the leading U.S. manufacturer of ammunition. Its largest business, Chlor Alkali Products and Vinyls, produces chlorine, caustic soda, ethylene dichloride (EDC), vinyl chloride monomer, chlorinated organics, hydrochloric acid, hydrogen, and bleach, and represented about 54% of 2025 sales. Olin is one of the world's largest chlor alkali producers, with roughly a fifth of North American capacity. The Epoxy segment (about 20% of 2025 sales) makes epoxy resins and precursors such as allyl chloride, epichlorohydrin, and phenol and acetone aromatics. The Winchester segment (about 26% of sales) produces sporting, law-enforcement, and small-caliber military ammunition, reloading components, and clay targets, and in April 2025 completed the acquisition of the small caliber ammunition assets of AMMO, Inc., adding a 185,000 square foot plant in Manitowoc, Wisconsin.

Full OLN guide

Occidental Petroleum (Oxy) is a large US-based oil and gas company with three main businesses. Upstream exploration and production is the core: Oxy finds and produces crude oil and natural gas, with a flagship position in the Permian Basin, the most prolific US oil field, plus operations in the Rocky Mountains, the Gulf of Mexico, and internationally. Its chemicals arm, OxyChem, is a major producer of chlor-alkali and PVC-related chemicals. Oxy is also building a carbon-management business through its 1PointFive subsidiary, developing direct air capture (DAC) facilities that pull CO2 from the atmosphere. The company makes most of its money selling oil and gas, so cash flow swings with commodity prices. Oxy is notable for Berkshire Hathaway's large ownership stake and for its 2019 acquisition of Anadarko, which left it heavily indebted. Headquartered in Houston, Texas, Oxy has since prioritized cutting debt and returning cash, while positioning carbon capture as a long-term option.

Full OXY guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• OLN drivers: Pending Merger of Equals with Huntsman; Chlor Alkali Pricing and ECU Recovery.
• OXY drivers: Permian Basin scale; Debt reduction and capital return.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Olin's earnings are highly cyclical and commodity-priced, so weak chlorine, caustic soda, EDC, and epoxy pricing can push results to a loss quickly, as the first quarter 2026 net loss of about $83 million showed. For OXY, oxy's earnings and cash flow are highly sensitive to oil and gas prices, which are volatile and outside its control.

Pick OLN if you believe its drivers more; OXY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the OLN and OXY guides.

OLN. Olin's trailing price-to-earnings ratio is negative because the trailing twelve months include losses, so investors lean on normalized mid-cycle earnings, EV/EBITDA, and the pending Huntsman exchange ratio instead of reported P/E. The share price near the low $20s and a market capitalization around $2.3 billion reflect a cyclical trough in chlor alkali and epoxy pricing plus deal uncertainty. These figures are approximate and move with commodity prices and merger developments.

OXY. Oxy's valuation is dominated by oil-price sensitivity and balance-sheet repair. Strong free cash flow at favorable commodity prices funds debt reduction and capital return, while the carbon-capture business adds long-dated optionality. The financial profile is that of a leveraged, cyclical Permian producer working to deleverage.

Headline figures (approximate, July 2026): OLN shows revenue (full year 2025) ~$6.7 billion, revenue (q1 2026) ~$1.58 billion (down ~4% year over year), net income (q1 2026) ~-$83 million (loss), ~-$0.73 per diluted share, adjusted ebitda (q1 2026) ~$86 million (down from ~$186 million a year earlier); OXY shows revenue (ttm) ~$27 billion, operating margin ~20%, highly oil-price dependent, production ~1.2+ million barrels of oil equivalent per day, free cash flow strong at mid-cycle oil prices.

OLN and OXY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined OLN and OXY exposure against your real portfolio. It is not an investment adviser.